Home › Myelodysplastic Syndromes › North Carolina › Durham
Myelodysplastic Syndromes clinical trials in Durham, NC
14 studies for Myelodysplastic Syndromes are looking for participants at sites in and around Durham (within about 30 miles). Open a study to see who can join and how to contact the study team.
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RecruitingPhase 2
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi away
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- Duke University Medical Center, Durham
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
RecruitingPhase 1
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi away
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
RecruitingPhase 3
- Unc Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi away
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RecruitingPhase 1/2
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi away
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
RecruitingPhase 1
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi away
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
RecruitingPhase 1/2
- Duke Cancer Institute, Durham
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
RecruitingPhase 1/2
- Research Site, Durham
- Research Site, Chapel Hill · 10 mi away
Registry of Older Patients With Cancer
RecruitingObservational study
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi away
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RecruitingPhase 2/3
- Duke University, Durham
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
RecruitingPhase 1/2
- Duke University, Durham
- UNC Hospital, Chapel Hill · 10 mi away
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
RecruitingPhase 1
- Duke Cancer Center, Durham
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Chapel Hill · 10 mi away
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RecruitingObservational study
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi away
About Myelodysplastic Syndromes
Myelodysplastic Syndromes (MDS) are rare. They are sometimes found during a routine blood test. Learn symptoms, risk factors, and treatment options.
More about Myelodysplastic Syndromes on MedlinePlus
Myelodysplastic Syndromes trials in other cities
- Houston, TX44 studies
- Baldwin Park, CA26 studies
- New York City, NY21 studies
- Seattle, WA21 studies
- Washington, DC20 studies
- Boston, MA20 studies
- Tampa, FL19 studies
- Miami, FL17 studies
- Columbus, OH14 studies
- St. Louis, MO14 studies
- Chicago, IL14 studies
- Atlanta, GA12 studies
Other studies in Durham
- Breast Cancer63 studies
- Cancer (all types)59 studies
- Non-Small Cell Lung Cancer39 studies
- Multiple Myeloma37 studies
- Acute Myeloid Leukemia33 studies
- Metastatic Cancer33 studies
- Lung Cancer32 studies
- Prostate Cancer32 studies
- Colorectal Cancer28 studies
- Chronic Lymphocytic Leukemia27 studies
- Ovarian Cancer27 studies
- Heart Failure26 studies
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.